AN OVERVIEW ON POLYCYSTIC OVARIAN SYNDROME

Authors

  • Sri Harika Yedulapuram Department of Pharmacy Practice, Sree Chaitanya institute of Pharmaceutical Sciences Thimmapur, Karimnagar, Telangana, India-505527
  • Mounika Gunda Department of Pharmacy Practice, Sree Chaitanya institute of Pharmaceutical Sciences Thimmapur, Karimnagar, Telangana, India-505527
  • Neethika Reddy Moola Department of Pharmacy Practice, Sree Chaitanya institute of Pharmaceutical Sciences Thimmapur, Karimnagar, Telangana, India-505527
  • Rohith Kumar Kadarla Department of Pharmacy Practice, Sree Chaitanya institute of Pharmaceutical Sciences Thimmapur, Karimnagar, Telangana, India-505527

DOI:

https://doi.org/10.22270/ajprd.v7i4.514

Keywords:

Polycystic Ovary Syndrome, hyperandrogenism, metabolic disorder.

Abstract

World Health Organization (WHO) estimates that PCOS has affected 116 million women (3.4%) worldwide in 2012 . Globally, prevalence estimates of PCOS are highly variable, ranging from 2.2% to as high as 26%. In India, experts claim 10% of the women to be affected by PCOS and yet no proper published statistical data on the prevalence of PCOS in India is available. Polycystic Ovary Syndrome (PCOS) is an endocrine metabolic disorder characterized by multiple hormonal imbalances representing diverse clinical presentations dominated by clinical and biochemical signs of hyperandrogenism which results in short and long term consequences in female health. A defect of the ovarian cells (most likely theca cells) is the underlying cause of PCOS, resulting in excessive androgen synthesis and the clinical and biochemical symptoms of the disease. In the literature, reference is made to the participation of genetic factors, including ethnicity; there is a higher frequency of PCOS in Spanish, Native American and Mexican women. The patient seeks a dermatology consultation for one or more complaints like acne, hirsutism, alopecia, acanthosis nigricans, skin tags and occasionally, darkening of complexion with weight gain. . If irregular menstrual cycles or primary infertility are the main complaints, the patient may consult a gynaecologist. Polycystic ovaries found on ultrasound scanning will often have no clinical effects, but PCOS is the most common diagnosis made in women presenting with amenorrhoea, oligomenorrhoea or heavy, irregular and prolonged periods. It is the commonest cause of hirsutism and of infertility due to anovulation. Women with PCOS have increased concentrations of circulating androgens and there is a marked association with insulin resistance, dyslipidaemia, obesity, gestational diabetes, type 2 diabetes and heart disease

 

Downloads

Download data is not yet available.

Author Biographies

Sri Harika Yedulapuram, Department of Pharmacy Practice, Sree Chaitanya institute of Pharmaceutical Sciences Thimmapur, Karimnagar, Telangana, India-505527

Department of Pharmacy Practice, Sree Chaitanya institute of Pharmaceutical Sciences Thimmapur, Karimnagar, Telangana, India

Mounika Gunda, Department of Pharmacy Practice, Sree Chaitanya institute of Pharmaceutical Sciences Thimmapur, Karimnagar, Telangana, India-505527

Department of Pharmacy Practice, Sree Chaitanya institute of Pharmaceutical Sciences Thimmapur, Karimnagar, Telangana, India-505527

Neethika Reddy Moola, Department of Pharmacy Practice, Sree Chaitanya institute of Pharmaceutical Sciences Thimmapur, Karimnagar, Telangana, India-505527

Department of Pharmacy Practice, Sree Chaitanya institute of Pharmaceutical Sciences Thimmapur, Karimnagar, Telangana, India-505527

Rohith Kumar Kadarla, Department of Pharmacy Practice, Sree Chaitanya institute of Pharmaceutical Sciences Thimmapur, Karimnagar, Telangana, India-505527

Department of Pharmacy Practice, Sree Chaitanya institute of Pharmaceutical Sciences Thimmapur, Karimnagar, Telangana, India-505527

References

1. Gautam N. Allahbadia, Rubina Merchant. Polycystic ovary syndrome and impact on health. (Middle East Fertility society Journal) 2011; 16:19-37.
2. Uche Anadu Ndefo, PharmD, BCPS; Angie Eaton, PharmD; and Monica RobinsonGreen, BCPS, BCACP. Polycystic Ovary Syndrome A Review of Treatment Options With a Focus on Pharmacological Approaches. (P&T). 2013; 38(6):336-355.
3. V. De Leo, M. C. Musacchio, V. Cappelli, M. G. Massaro, G. Morgante and F. Petraglia. Genetic, hormonal and metabolic aspects of PCOS: an update. (Reproductive Biology and Endocrinology). 2016; 14(38).
4. Choudhary A, Jain S, Chaudhari P Prevalence and symptomology of polycystic ovarian syndrome in Indian women: is there a rising incidence? (International Journal of Reproduction, Contraception, Obstetrics and Gynecology) 2017; 6 (11):4971-4975.
5. Susan M Sirmans Kristen A Pate. Epidemiology, diagnosis, and management of polycystic ovary syndrome. (Dovepress) 2014; 6: 1-13.
6. Wołczyński S, Zgliczyński W. Abnormalities of the menstrual cycle. In: Large Interna – Endocrinology. 2nd edition. Medical Tribune Poland, Warsaw 2012, 561–567.
7. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1):41–47. 10.1093/humrep/deh098.
8. Milewicz A. Reimbursement of metformin for polycystic ovary syndrome. Endokrynol Pol. 2013; 64(5):409–414. 10.5603/EP.2013.0025.
9. Morotti E, Battaglia B, Fabbri R, Paradisi R, Venturoli S, Battaglia C. Cigarette smoking and cardiovascular risk in young women with polycystic ovary syndrome. Int J Fertil Steril. 2014; 7(4):301–312.
10. Davies MJ, Marino JL, Willson KJ, March WA, Moore VM. Intergenerational associations of chronic disease and polycistic ovary syndrome. PLoS One. 2011; 6(10):e25947.
11. Tan S, Scherag A, Janssen OE et al. Large effects on body mass index and insulin resistance women with PCOS (FTO) variants in patients with polycystic ovary syndrome (PCOS). BMC Med Genet. 2010; 11:12.
12. Fica S, Albu A, Constantin M, Dobri GA, Davila C. Insulin resistance and fertility in polycystic ovary syndrome. J Med Life. 2008; 1(4):415– 422.
13. Traub ML. Assessing and treating insulin resistance in women with polycystic ovarian syndrome. World J Diabetes. 2011; 2(3):33–40.
14. Sathyapalan T, Atkin ST. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediat Inflamm. 2010; 2010:
15. Kharitonenkov A, Adams AC. Inventing new medicines: The FGF21 story. Mol Metab. 2014; 3:221–229. 10.1016/j.molmet.2013.12. 003.
16. McClung J, Karl P. Iron deficiency and obesity: The contribution of inflammation and diminished iron absorption. Nutr Rev. 2009; 67: 100–104.
17. Bentley-Lewis R, Selly E, Dunaif A. Ovarian hypertension: Polycystic ovary syndrome. Endocrinol Metab Clin North Am. 2011; 40:433–449.
18. Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004; 18:737-54.


19. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol 2003; 101:995-1007.
20. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: A randomized study. J Clin Endocrinol Metab 2000; 85:3161-8.
21. Olsen EA. Female pattern hair loss. J Am Acad Dermatol 2001; 45:70-80.
22. Park JC, Lim SY, Jang TK, Bae JG, Kim JI, Rhee JH. Endometrial histology and predictable clinical factors for endometrial disease in women with polycystic ovary syndrome. Clin Exp Reprod Med 2011; 38:42-6
23. Samer ElHayek1, LynnBitar, LayalH.Hamdar1, FadiG.Mirza and Georges Daoud1. Poly Cystic Ovarian Syndrome: An Updated Overview. (Frontiers in Physiology) 2016; 7(124).
24. Joselyn Rojas, Mervin Chávez, Luis Olivar Milagros Rojas, JesseniaMorillo, JoséMejías, María Calvo, and Valmore Bermúdez1. Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth. (International Journal of Reproductive Medicine) 2014
25. Dinka Pavicic Baldani, Lana Skrgatic, and Roya Ougouag. Polycystic Ovary Syndrome: Important Underrecognised Cardiometabollic Risk Factor in Reproductive- Age Women. (International Journal of Endocrinology) 2015
26. Susan Sam, MD. Obesity and Polycystic Ovary Syndrome. (NIH Obes Manag) 2007; 3(2): 69–73.
27. Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysis. 2009; 13(2): 90-92.
28. Stefano Palomba, Susanna Santagni, et al. Complications and challenges associated with cPolycysti ovary syndrome: current perspectives. (International Journal of Women’s Health) 2015; 7:745-763.
29. Andrea Dunaif. Insulin Resistance and the Polycystic Ovary Syndrome:Mechanism and Implications for Pathogenesis. (Endocrine Reviews) 18(6): 774-800.
30. Crystal C. Douglas, Ph.D., R.D.a,b, Barbara A. Gower, Ph.D.a, Betty E. Darnell, M.S., R.D.b,et al. Role of diet in the treatment of polycystic ovary syndrome. (American Society for Reproductive Medicine) 2006; 85(3):679-688.
31. H. Farshchi, A. Rane, A. Love & R. L. Kennedy. Diet and nutrition in polycystic ovary syndrome (PCOS): Pointers for nutritional management. (Journal of Obstetrics and Gynaecology); 27(8):762 – 773.
32. Artemis aki, lKarkanoannis Kalogiannidis and Dimitrios Panidis. Effects of Lifestyle Modification on Pregnancy Success in Obese and Overweight Women with PCOS. (J Women’s Health Care) 2013; 2(2).
33. Cheryce L. Harrison, Catherine B. Lombard , Lisa J. Moran , and Helena J. Teede Exercise therapy in polycystic ovary syndrome: a systematic review. (Human Reproduction Update) 2011; 17(2):171–183.
34. Polycystic Ovary Syndrome. (Saskatchewan Drug Information Services) 2004; 21(1).
35. Sanam Lathief, Lubna Pal, Advances In Treatment Options For Polycystic Ovary Syndrome - Us Endocrinology, 2012;8(1):57-64

Published

2019-08-15

How to Cite

Yedulapuram, S. H., Gunda, M., Moola, N. R., & Kadarla, R. K. (2019). AN OVERVIEW ON POLYCYSTIC OVARIAN SYNDROME. Asian Journal of Pharmaceutical Research and Development, 7(4), 72–80. https://doi.org/10.22270/ajprd.v7i4.514